Primary Objective:
To evaluate the safety of aflibercept in participants with mCRC treated with
irinotecan/5-Fluorouracil (5-FU) combination (FOLFIRI) after failure of an oxaliplatin-based
regimen (participants similar to those evaluated in the VELOUR trial [EFC10262, NCT00561470])
according to side effects prevention and management guidelines.
Secondary Objective:
To document the Health-Related Quality of Life (HRQL) of aflibercept in this participant
population.